The Effect of Retrograde Autologous Priming on Transfusion Requirements After Cardiac Surgery

Launched by POPULATION HEALTH RESEARCH INSTITUTE · Jan 18, 2024

Keywords

ClinConnect Summary

The TheRAPy vanguard trial is a research study looking at how different methods of preparing patients for heart surgery might affect the need for blood transfusions. Specifically, it compares two approaches: one that uses a technique called retrograde autologous priming (RAP) and another that uses a common fluid called crystalloid priming. The goal is to find out if using RAP can help reduce the number of red blood cell transfusions needed during heart surgery, which is often done with the help of a heart-lung machine.

To participate in this trial, hospitals need to perform more than 200 adult heart surgeries each year, and a majority of the surgical team must agree to follow the trial's procedures. If you or a loved one is having heart surgery at a participating hospital during the trial, you may be included in the study. Participants will be monitored to see how well these two methods work in practice. This trial is an important step toward understanding how to improve care for heart surgery patients and reduce the need for blood transfusions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Hospitals completing \>200 adult cardiac surgical cases a year; (ii) 95% of cardiovascular surgery group (i.e., cardiac anesthesiologists, surgeons, and perfusionists) agree to manage patients under both autologous priming policies as per their randomization schedule for the duration of the trial.
• • All patients undergoing cardiac surgery on cardiopulmonary bypass at an enrolled site during the trial period will be included in data collection.
• Exclusion Criteria:
• • Complete \<=200 cardiac surgical cases.
• • \<95% of their cardiovascular surgery group agrees to manage patients according to either of the two policies.